NasdaqCM:VKTXBiotechs
Why Viking Therapeutics (VKTX) Is Up 22.2% After Advancing VK3019 Into First-in-Human Obesity Trial
Viking Therapeutics recently initiated a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor agonist for obesity, following US FDA clearance of its IND and adding to its expanding metabolic disease pipeline.
This move, alongside ongoing late-stage development of injectable and planned oral VK2735, signals Viking’s intent to build a differentiated, multi-mechanism obesity franchise spanning both delivery routes.
We’ll now explore how advancing VK3019 into...